Correlation Between Zentalis Pharmaceuticals and Eterna Therapeutics

Can any of the company-specific risk be diversified away by investing in both Zentalis Pharmaceuticals and Eterna Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zentalis Pharmaceuticals and Eterna Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zentalis Pharmaceuticals Llc and Eterna Therapeutics, you can compare the effects of market volatilities on Zentalis Pharmaceuticals and Eterna Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zentalis Pharmaceuticals with a short position of Eterna Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zentalis Pharmaceuticals and Eterna Therapeutics.

Diversification Opportunities for Zentalis Pharmaceuticals and Eterna Therapeutics

0.06

Correlation Coefficient

Zentalis Pharmaceuticals  Eterna Therapeutics

Significant diversification

The 3 months correlation between Zentalis and Eterna is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Zentalis Pharmaceuticals Llc and Eterna Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eterna Therapeutics and Zentalis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zentalis Pharmaceuticals Llc are associated (or correlated) with Eterna Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eterna Therapeutics has no effect on the direction of Zentalis Pharmaceuticals i.e., Zentalis Pharmaceuticals and Eterna Therapeutics go up and down completely randomly.

Pair Corralation between Zentalis Pharmaceuticals and Eterna Therapeutics

Given the investment horizon of 90 days Zentalis Pharmaceuticals Llc is expected to under-perform the Eterna Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Zentalis Pharmaceuticals Llc is 1.51 times less risky than Eterna Therapeutics. The stock trades about -0.08 of its potential returns per unit of risk. The Eterna Therapeutics is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  28.00  in Eterna Therapeutics on December 28, 2024 and sell it today you would lose (5.00) from holding Eterna Therapeutics or give up 17.86% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.36%
Values	Daily Returns

Zentalis Pharmaceuticals Llc  vs.  Eterna Therapeutics

Zentalis Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Zentalis Pharmaceuticals Llc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Eterna Therapeutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Eterna Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Eterna Therapeutics may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Zentalis Pharmaceuticals and Eterna Therapeutics

The main advantage of trading using opposite Zentalis Pharmaceuticals and Eterna Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zentalis Pharmaceuticals position performs unexpectedly, Eterna Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eterna Therapeutics will offset losses from the drop in Eterna Therapeutics' long position.

The idea behind Zentalis Pharmaceuticals Llc and Eterna Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.